

Tickers: FHH/FHH.F

Quarter End Statement of Investments

3rd Quarter as at September 30, 2025

Industry Allocation	% of Net Asset Value
Pharmaceuticals and Biotechnology	45.14%
Medical Equipment and Services	31.99%
Health Care Providers	22.92%
Cash & Cash Equivalents	0.13%
Total	100.18%
Other Assets and Liabilities	(0.18%)
Total Net Asset Value	100.00%

Top 25 Holdings	% of Net Asset Value
United Therapeutics Corporation	3.06%
Insmmed, Inc.	3.00%
Elanco Animal Health, Inc.	2.96%
Tempus AI, Inc. (Class A)	2.66%
Jazz Pharmaceuticals Plc	2.61%
Universal Health Services, Inc. (Class B)	2.37%
Biogen, Inc.	2.34%
Alnylam Pharmaceuticals, Inc.	2.34%
Acadia Healthcare Company, Inc.	2.29%
Zimmer Biomet Holdings, Inc.	2.26%
Regeneron Pharmaceuticals, Inc.	2.24%
Merck & Co., Inc.	2.22%
Johnson & Johnson	2.04%
Exelixis, Inc.	1.97%
Cardinal Health, Inc.	1.96%
Avantor, Inc.	1.94%
UnitedHealth Group, Inc.	1.86%
HCA Healthcare, Inc.	1.86%
Organon & Co.	1.85%
Humana, Inc.	1.79%
Pfizer, Inc.	1.76%
Veeva Systems, Inc. (Class A)	1.74%
Abbott Laboratories	1.65%
BioMarin Pharmaceutical, Inc.	1.65%
Insulet Corporation	1.65%
Total Net Asset Value	\$11,131,485

Commissions, management fees and expenses all may be associated with ETF investments. Please carefully read the simplified prospectus of the ETF before investing. ETFs are not guaranteed, their values change frequently and past performance may not be repeated. Data is as of September 30, 2025 (unaudited).

(10/25)